Pfizer Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents 12 to 15 years of age
In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants ...
Read moreIn a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants ...
Read morePfizer Inc. and BioNTech SE today announced the signing of a Memorandum of Understanding (MoU) with ...
Read morePfizer and BioNTech announced they have submitted a variation to the Conditional Marketing Authorization (CMA) in ...
Read morePfizer & BioNTech today announced they will supply an additional 100 million doses of COMIRNATY®, the ...
Read moreIn participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those ...
Read morePfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Medicines Agency (EMA) approved ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.